JUPITER NEUROSCIENCES, INC. 发布了一份补充招股说明书，更新、修订并补充了2025年12月11日发布的招股说明书（“招股说明书”）。该补充招股说明书作为其S-1注册声明（注册号333-291832）的一部分，旨在更新、修订并补充招股说明书中包含的信息，这些信息包含在其于2026年6月22日向美国证券交易委员会（“SEC”）提交的当前报告8-K中（“当前报告”）。因此，公司已将当前报告附于本补充招股说明书中。本补充招股说明书中使用的首字母大写术语，除非在本补充招股说明书中另有定义，否则具有招股说明书中规定的含义。
本补充招股说明书并非完整，除非与招股说明书一起阅读，否则无法完整。本补充招股说明书应与招股说明书一起阅读，招股说明书应随本补充招股说明书交付，并参照其内容，但本补充招股说明书中的信息更新或取代了招股说明书中包含的信息。请将本补充招股说明书与您的招股说明书一起保存，以供将来参考。
公司普通股，面值0.0001美元每股（“普通股”），在纳斯达克股票市场，LLC上市，股票代码为“JUNS”。2026年6月18日，公司普通股的收盘价为0.2380美元每股。
投资我们的证券涉及在招股说明书的“风险因素”部分中描述的风险。
SEC或任何州证券委员会均未批准或否决根据招股说明书或本补充招股说明书发行的证券，也未确定招股说明书或本补充招股说明书是否真实或完整。任何相反的陈述都是刑事犯罪。
本补充招股说明书的日期为2026年6月22日。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
June 17, 2026
Date of Report (Date of earliest event reported)
JUPITER NEUROSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 17, 2026, Allison W. Brady, a member of the Board of Directors (the “Board”) of Jupiter Neurosciences, Inc. (the“Company”), informed the Company of her decision to resign from the Board, effective immediately. Ms. Brady also resigned fromher positions as a member of the Audit Committee and the Compensation Committee of the Board, effective as of the same date. Herdecision to resign is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policiesor practices. Ms. Brady’s seat on the Board will remain vacant until the Company’s annual meeting on July 22, 2026.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on itsbehalf by the undersigned hereunto duly authorized.
JUPITER NEUROSCIENCES, INC.
Date: June 22, 2026
By:/s/ Christer Rosén
Name: Christer Rosén
Title: Chief Executive Officer
